Lack of Effects of HER-2/neu on Prognosis in Colorectal Cancer: a Meta-analysis

Han, Jun; Meng, Qingcai; Liu, Xiao; Xi, Qiulei; Zhuang, Qiulin; Wu, Guohao

doi:10.7314/apjcp.2014.15.14.5551

Cited by 4 publications

(2 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In line with several studies of CRC patients [ 26 ][ 27 ], we did not find a prognostic benefit for patients with a positive HER-2 status or any correlation between positive HER-2 status and clinico-pathological parameters. As demonstrated in our preliminary studies [ 23 ], high HER-2 expression was found mainly in primary tumors in rectal cancer patients ( n = 4; 18.2%).…”

Section: Discussionsupporting

confidence: 89%

“…In several published meta-analyses it has been shown that HER-2 overexpression was correlated with decreased survival in CRC patients suggesting that HER-2 overexpression might not be a prognostic indicator [ 26 ][ 27 ]. In metastatic CRC, Aprile et al [ 28 ] reported a negative prognostic value of HER-2 expression in brain metastases.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

HER-2 and HER-3 expression in liver metastases of patients with colorectal cancer

Styczen

Nagelmeier²,

Beißbarth

et al. 2015

Oncotarget

View full text Add to dashboard Cite

ObjectiveIn this study, we evaluate the frequency of HER-2 and HER-3 expression in liver metastases from patients with colorectal cancer (CRLM). We analyzed the potential of HER-2 and HER-3 as therapeutic targets and evaluated their prognostic value.Patients and MethodsOverall 208 patients with CRLM were enrolled. HER-2 and HER-3 expression were determined in metastatic tissue of diagnostic punch biopsies (n = 29) or resection specimens (n = 179). The results of immunohistochemistry (IHC) scoring and In-situ-hybridization (ISH)-amplification were correlated with clinical parameters and for the 179 resected patients with cancer-specific (CSS) and overall survival (OS). The mean follow-up time was 56.7 months.ResultsPositivity of HER-2 status (IHC score 2+/ISH+ and IHC 3+) was found in 8.2% of CRLM. High expression of HER-3 (IHC score 2+ and IHC 3+) was detected in 75.0% of liver metastases. CSS after liver surgery was determined and was independent from the HER-2 status (p = 0.963); however HER-3 was prognostic with a favorable course for patients showing an overexpression of HER-3 (p = 0.037).ConclusionsHER-2 overexpression occurs in only 8% of patients with CRLM but with 75% of cases HER-3 is frequently overexpressed in CRLM. Therefore, HER-2 and particularly HER-3 could serve as novel targets to be addressed within multimodal treatment approaches.

show abstract

Section: Discussionsupporting

confidence: 89%

Section: Introductionmentioning

confidence: 99%

HER-2 and HER-3 expression in liver metastases of patients with colorectal cancer

Styczen

Nagelmeier²,

Beißbarth

et al. 2015

Oncotarget

View full text Add to dashboard Cite

show abstract

Association of HER2 codon 655 polymorphism with ovarian cancer

et al. 2015

View full text Add to dashboard Cite

The role of the human epidermal growth factor receptor 2 (HER2) codon 655 (Ile655Val) polymorphism in ovarian cancer is not fully understood. Two studies indicated a possible association between the Val allele and elevated risk or reduced prognosis of ovarian cancer. We investigated the HER2 codon 655 (rs1136201) polymorphism in 242 Austrian women-142 ovarian cancer patients and 100 healthy controls-by polymerase chain reaction and pyrosequencing. Associations between Ile655Val polymorphism and clinicopathological variables (e.g., age, FIGO stage, grading, serous vs. non-serous histology) were evaluated. The genotype distributions in ovarian cancer patients and controls were: AA; 66.2 %, AG; 25.35 %, GG; 8.45 %, and AA; 63 %, AG; 34 %, GG; 3.7 %, respectively (OR 1.15, CI 95 % 0.67-1.96). We observed a non-significant trend toward elevated cancer risk in Val/Val genotype (OR 2.98, CI 95 % 0.82-10.87, p = 0.10). Of note, 11 out of 12 Val/Val homozygotes were postmenopausal. The link between the Val/Val homozygosity and age over 50 years at diagnosis (OR 0.15, CI 95 % 0.02-1.2) was barely significant (p = 0.056). Summarizing, our data indicated a non-significant trend toward increased ovarian cancer risk in the Val/Val homozygosity, especially in women aged above 50 years. Further large-cohort studies focusing on the role of the HER2 codon 655 Val allele are needed.

show abstract

Expression of Beclin 1 and Bcl‑2 in pancreatic neoplasms and its effect on pancreatic ductal adenocarcinoma prognosis

Song

Wang

et al. 2017

Oncol Lett

View full text Add to dashboard Cite

Aberrant expression of Beclin 1 and B-cell lymphoma-2 (Bcl-2) has been identified in a variety of human tumors; however, little information is available for pancreatic neoplasms. The present study analyzed the expression of Beclin 1 and Bcl-2 in pancreatic ductal adenocarcinoma (PDAC) and solid pseudopapillary neoplasm (SPN) of the pancreas, and evaluated their prognostic significance for PDAC. The present study included 117 PDAC, 43 SPN and 32 chronic pancreatitis (CP) cases. Levels of Beclin 1 and Bcl-2 expression were evaluated semiquantitatively by immunohistochemistry, and their correlation with the survival of patients with PDAC was determined. Beclin 1 was upregulated in 74 (63.2%) PDAC, 26 (60.5%) SPN, and 14 (43.8%) CP cases. Bcl-2 was upregulated in 38 (32.5%) PDAC, 11 (25.6%) SPN and 24 (75.0%) CP cases. High Beclin 1 and low Bcl-2 expression was significantly correlated with poor differentiation and distant metastasis in PDAC, and associated with the presence of nuclear pleomorphism in SPN and with advanced Tumor-Node-Metastasis stage in PDAC. Beclin 1 and Bcl-2 levels were inversely correlated in PDAC, whereas they were positively correlated in SPN. Low Beclin 1 and high Bcl-2 expression was associated with improved disease-free survival and overall survival (OS). However, the association of Beclin 1 with survival was not significant in the Cox analysis, whereas Bcl-2 expression was significantly correlated with OS in the multivariate analysis. In conclusion, Beclin 1 upregulation exacerbated the progression and aggressiveness of pancreatic neoplasms, and Bcl-2 downregulated expression was an independently poor prognostic factor for PDAC.

show abstract

Lack of Effects of HER-2/neu on Prognosis in Colorectal Cancer: a Meta-analysis

Cited by 4 publications

References 51 publications

HER-2 and HER-3 expression in liver metastases of patients with colorectal cancer

HER-2 and HER-3 expression in liver metastases of patients with colorectal cancer

Association of HER2 codon 655 polymorphism with ovarian cancer

Expression of Beclin 1 and Bcl‑2 in pancreatic neoplasms and its effect on pancreatic ductal adenocarcinoma prognosis

Contact Info

Product

Resources

About